Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Optimal disease management and health monitoring in adults with sickle cell disease

Jo Howard, Swee Lay Thein

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 505–512.

https://doi.org/10.1182/hematology.2019000055

Published: 2019

Journal Articles

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

Barbara Eichhorst, Moritz Fürstenau, Michael Hallek

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 482–489.

https://doi.org/10.1182/hematology.2019000070

Published: 2019

Journal Articles

Ready for prime time: role for geriatric assessment to improve quality of care in hematology practice

Heidi D. Klepin

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 53–58.

https://doi.org/10.1182/hematology.2019001299

Published: 2019

Journal Articles

Management of older Hodgkin lymphoma patients

Andrew M. Evens, Jordan Carter, Kah Poh Loh, Kevin A. David

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 233–242.

https://doi.org/10.1182/hematology.2019000028

Published: 2019

Journal Articles

Integrating patient-centered factors in the risk assessment of MDS

Rena J. Buckstein

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 373–380.

https://doi.org/10.1182/hematology.2019000041

Published: 2019

Journal Articles

Cytotoxic therapy in acute myeloid leukemia: not quite dead yet

Laura C. Michaelis

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 51–62.

https://doi.org/10.1182/asheducation-2018.1.51

Published: 2018

Journal Articles

Selecting Frontline Therapy for CLL in 2018

Nitin Jain

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 242–247.

https://doi.org/10.1182/asheducation-2018.1.242

Published: 2018

Journal Articles

Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents

Olatoyosi Odenike

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 460–469.

https://doi.org/10.1182/asheducation-2017.1.460

Published: 2017

Journal Articles

How should we sequence and combine novel therapies in CLL?

Matthew S. Davids

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 346–353.

https://doi.org/10.1182/asheducation-2017.1.346

Published: 2017

Journal Articles

Safety profiles of novel agent therapies in CLL

Inhye E. Ahn, Matthew S. Davids

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 354–357.

https://doi.org/10.1182/asheducation-2017.1.354

Published: 2017

Journal Articles

Sequencing of chronic lymphocytic leukemia therapies

Jacqueline C. Barrientos

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 128–136.

https://doi.org/10.1182/asheducation-2016.1.128

Published: 2016

Journal Articles

First-line therapy for young patients with CLL

Nitin Jain, Susan O’Brien

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 146–148.

https://doi.org/10.1182/asheducation-2016.1.146

Published: 2016

Journal Articles

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults

Mohamed L. Sorror, Elihu Estey

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 21–33.

https://doi.org/10.1182/asheducation-2014.1.21

Published: 2014

Journal Articles

Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia

Heidi D. Klepin

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 8–13.

https://doi.org/10.1182/asheducation-2014.1.8

Published: 2014

Journal Articles

Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights

Uwe Platzbecker

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 522–528.

https://doi.org/10.1182/asheducation-2013.1.522

Published: 2013

Journal Articles

Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers

Tait Shanafelt

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 158–167.

https://doi.org/10.1182/asheducation-2013.1.158

Published: 2013

Journal Articles

Pulmonary Hypertension, Tricuspid Regurgitant Velocity Screening, and the Nitric Oxide Pathway

Kathryn L. Hassell

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 419–426.

https://doi.org/10.1182/asheducation-2011.1.419

Published: 2011

Journal Articles

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndrome

Corey Cutler

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 325–329.

https://doi.org/10.1182/asheducation-2010.1.325

Published: 2010

Journal Articles

Comorbidities and Hematopoietic Cell Transplantation Outcomes

Mohamed L. Sorror

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 237–247.

https://doi.org/10.1182/asheducation-2010.1.237

Published: 2010

Journal Articles

Outcomes with Myeloid Malignancies

Bart L. Scott, Brenda M. Sandmaier

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 381–389.

https://doi.org/10.1182/asheducation-2006.1.381

Published: 2006

NARROW

Optimal disease management and health monitoring in adults with sickle cell disease

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

Ready for prime time: role for geriatric assessment to improve quality of care in hematology practice

Management of older Hodgkin lymphoma patients

Integrating patient-centered factors in the risk assessment of MDS

Cytotoxic therapy in acute myeloid leukemia: not quite dead yet

Selecting Frontline Therapy for CLL in 2018

Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents

How should we sequence and combine novel therapies in CLL?

Safety profiles of novel agent therapies in CLL

Sequencing of chronic lymphocytic leukemia therapies

First-line therapy for young patients with CLL

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults

Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia

Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights

Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers

Pulmonary Hypertension, Tricuspid Regurgitant Velocity Screening, and the Nitric Oxide Pathway

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndrome

Comorbidities and Hematopoietic Cell Transplantation Outcomes

Outcomes with Myeloid Malignancies

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only